A retrospective study comparing the treatment outcomes of Abiraterone Acetate in metastatic castration-resistant prostate cancer (mCRPC) patients who had Eastern Cooperative Oncology Group (ECOG) performance status 0–1 and ≥2.
Phase of Trial: Phase IV
Latest Information Update: 05 Apr 2016
At a glance
- Drugs Abiraterone acetate (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 05 Apr 2016 New trial record